However, the anti‐tumor efficacy of nivolumab for NSCLC was positively correlated with the level of PD‐L1 expression in terms of both PFS (compared with docetaxel, HR: <1%→≥1%→≥5%→≥10%, 0.90→0.69→0.54→0.54) and OS (compared with docetaxel, HR: <1%→≥1%→≥5%→≥10%→≥50%, 0.74→0.66→0.50→0.49→0.42) (Figures 2, 3, 8, S2 and S3). Here, CD274 is linked to non-small cell lung carcinoma.